SOURCE: The Bedford Report

The Bedford Report

July 14, 2011 08:16 ET

Pipelines and Patents Continue to Drive the Biotech Sector

The Bedford Report Provides Equity Research on CytRx & PDL BioPharma

NEW YORK, NY--(Marketwire - Jul 14, 2011) - According the World Health Organization, cancer will become the leading cause of death worldwide this year. Cancer has already emerged as the most expensive disease -- costing the global economy nearly a trillion dollars a year. With cancer drugs alone costing the United States more than $30 million a year, it is clearly a lucrative sector for drug makers. The Bedford Report examines the outlook for companies in the Healthcare Sector and provides equity research on CytRx Corporation (NASDAQ: CYTR) and PDL BioPharma, Inc. (NASDAQ: PDLI). Access to the full company reports can be found at:

www.bedfordreport.com/CYTR
www.bedfordreport.com/PDLI

Cancer medication is also an inherently risky sector. Earlier this year Reuters published research from BioMed Tracker and BIO, which claims that the cancer drug success rate is a mere 4.7 percent. Upon revealing the study, the agency's Oncologic Drugs Advisory Committee endorsed several FDA proposals for tightening the accelerated approval standards, recommending that sponsors generally be required to conduct randomized trials rather than single-arm studies, and that there be more extensive postmarketing studies to confirm clinical benefit.

The Bedford Report releases investment research on the Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

CytRx Corporation is a biopharmaceutical research and development oncology company engaged in the development of high-value human therapeutics. Shares of the company have been on the upswing in recent weeks after the drug developer announced that it received special regulatory designation for an experimental drug meant to treat a type of cancer that affects soft tissue.

PDL pioneered the humanization of monoclonal antibodies, which enabled the discovery of a new generation of targeted treatments for cancer and immunologic disease. The company receives royalties on sales of a number of humanized antibody products marketed by leading pharmaceutical and biotechnology companies today based on patents which expire in late 2014. Presently PDL pays an annual dividend of 60 cents a share for a hefty yield of around 9.5 percent.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer

Contact Information